Literature DB >> 33256909

Selection of allogeneic hematopoietic cell transplant donors to optimize natural killer cell alloreactivity.

Brian C Shaffer1, Katharine C Hsu2.   

Abstract

Natural killer (NK) cells are potent mediators of the graft versus leukemia phenomenon critical to the success of allogeneic hematopoietic cell transplantation. Central to calibrating NK effector function via their interaction with class I human leukocyte antigens are the numerous inhibitory killer Ig-like receptors (KIR). The KIR receptors are encoded by a family of polymorphic genes, whose expression is largely stochastic and uninfluenced by human leukocyte antigens genotype. These features provide the opportunity to select hematopoietic cell donors with favorable KIR genotypes that confer enhanced protection from relapse via NK-mediated graft versus leukemia. Over the last 2 decades, a large body of work has emerged examining the use of KIR genotyping to stratify potential donors based on anticipated NK alloreactivity. Overall, these results support KIR-based donor selection for patients undergoing allogeneic hematopoietic cell transplantation for a diagnosis of acute myelogenous leukemia. Despite this, the underlying factors that control NK cell responsiveness are not completely understood, and opportunities remain to refine donor selection using NK cell receptor genotyping. In this review, we will summarize the relevant findings with respect to KIR genotyping as a selection parameter for allogeneic hematopoietic cell donors and address practical considerations with respect to KIR-based selection of donors for patients with myeloid neoplasia.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Acute myeloid leukemia; Allogeneic hematopoietic cell transplantation; HLA; KIR; Natural Killer Cells

Mesh:

Year:  2020        PMID: 33256909      PMCID: PMC7708684          DOI: 10.1053/j.seminhematol.2020.10.005

Source DB:  PubMed          Journal:  Semin Hematol        ISSN: 0037-1963            Impact factor:   3.851


  91 in total

1.  Identification of probabilistic transcriptional switches in the Ly49 gene cluster: a eukaryotic mechanism for selective gene activation.

Authors:  Ali Saleh; Gareth E Davies; Veronique Pascal; Paul W Wright; Deborah L Hodge; Edward H Cho; Stephen J Lockett; Mehrnoosh Abshari; Stephen K Anderson
Journal:  Immunity       Date:  2004-07       Impact factor: 31.745

2.  KIR2DS1-positive NK cells mediate alloresponse against the C2 HLA-KIR ligand group in vitro.

Authors:  Joseph H Chewning; Charlotte N Gudme; Katharine C Hsu; Annamalai Selvakumar; Bo Dupont
Journal:  J Immunol       Date:  2007-07-15       Impact factor: 5.422

3.  Expression of the HLA-C2-specific activating killer-cell Ig-like receptor KIR2DS1 on NK and T cells.

Authors:  Céline Cognet; Catherine Farnarier; Laurent Gauthier; Coralie Frassati; Pascale André; Aude Magérus-Chatinet; Nicolas Anfossi; Frederic Rieux-Laucat; Eric Vivier; Nicolas Schleinitz
Journal:  Clin Immunol       Date:  2010-01-25       Impact factor: 3.969

4.  Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. II. Characterization of effector cells.

Authors:  R B Herberman; M E Nunn; H T Holden; D H Lavrin
Journal:  Int J Cancer       Date:  1975-08-15       Impact factor: 7.396

5.  "Natural" killer cells in the mouse. II. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Characteristics of the killer cell.

Authors:  R Kiessling; E Klein; H Pross; H Wigzell
Journal:  Eur J Immunol       Date:  1975-02       Impact factor: 5.532

6.  MHC class I-specific inhibitory receptors and their ligands structure diverse human NK-cell repertoires toward a balance of missing self-response.

Authors:  Makoto Yawata; Nobuyo Yawata; Monia Draghi; Fotini Partheniou; Ann-Margaret Little; Peter Parham
Journal:  Blood       Date:  2008-06-26       Impact factor: 22.113

7.  Down-regulation of the class I HLA heterodimer and beta 2-microglobulin on the surface of cells infected with cytomegalovirus.

Authors:  P D Barnes; J E Grundy
Journal:  J Gen Virol       Date:  1992-09       Impact factor: 3.891

8.  The effect of donor characteristics on survival after unrelated donor transplantation for hematologic malignancy.

Authors:  Craig Kollman; Stephen R Spellman; Mei-Jie Zhang; Anna Hassebroek; Claudio Anasetti; Joseph H Antin; Richard E Champlin; Dennis L Confer; John F DiPersio; Marcelo Fernandez-Viña; Robert J Hartzman; Mary M Horowitz; Carolyn K Hurley; Chatchada Karanes; Martin Maiers; Carlheinz R Mueller; Miguel-Angel Perales; Michelle Setterholm; Ann E Woolfrey; Neng Yu; Mary Eapen
Journal:  Blood       Date:  2015-11-02       Impact factor: 22.113

9.  NK cell recovery after haploidentical HSCT with posttransplant cyclophosphamide: dynamics and clinical implications.

Authors:  Antonio Russo; Giacomo Oliveira; Sofia Berglund; Raffaella Greco; Valentina Gambacorta; Nicoletta Cieri; Cristina Toffalori; Laura Zito; Francesca Lorentino; Simona Piemontese; Mara Morelli; Fabio Giglio; Andrea Assanelli; Maria Teresa Lupo Stanghellini; Chiara Bonini; Jacopo Peccatori; Fabio Ciceri; Leo Luznik; Luca Vago
Journal:  Blood       Date:  2017-10-06       Impact factor: 22.113

10.  Natural killer cell education in mice with single or multiple major histocompatibility complex class I molecules.

Authors:  Sofia Johansson; Maria Johansson; Eleftheria Rosmaraki; Gustaf Vahlne; Ramit Mehr; Mali Salmon-Divon; François Lemonnier; Klas Kärre; Petter Höglund
Journal:  J Exp Med       Date:  2005-04-04       Impact factor: 14.307

View more
  4 in total

1.  Practical Considerations and Workflow in Utilizing KIR Genotyping in Transplantation Medicine.

Authors:  Makoto Yawata; Nobuyo Yawata
Journal:  Methods Mol Biol       Date:  2022

Review 2.  Immune Reconstitution after Haploidentical Donor and Umbilical Cord Blood Allogeneic Hematopoietic Cell Transplantation.

Authors:  Hany Elmariah; Claudio G Brunstein; Nelli Bejanyan
Journal:  Life (Basel)       Date:  2021-01-29

3.  Allele imputation for the killer cell immunoglobulin-like receptor KIR3DL1/S1.

Authors:  Genelle F Harrison; Laura Ann Leaton; Erica A Harrison; Katherine M Kichula; Marte K Viken; Jonathan Shortt; Christopher R Gignoux; Benedicte A Lie; Damjan Vukcevic; Stephen Leslie; Paul J Norman
Journal:  PLoS Comput Biol       Date:  2022-02-22       Impact factor: 4.475

Review 4.  Harnessing CD16-Mediated NK Cell Functions to Enhance Therapeutic Efficacy of Tumor-Targeting mAbs.

Authors:  Cristina Capuano; Chiara Pighi; Simone Battella; Davide De Federicis; Ricciarda Galandrini; Gabriella Palmieri
Journal:  Cancers (Basel)       Date:  2021-05-20       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.